FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092120000> ?p ?o ?g. }

• W2092120000 endingPage "2744" @default.
• W2092120000 startingPage "2738" @default.
• W2092120000 abstract "Mediastinal recurrence remains the most common cause of failure in patients with mediastinal T-cell lymphoblastic lymphoma (LBL). The role of mediastinal radiation therapy in improving local disease control and overall prognosis is not well-known with modern intensive chemotherapy. The objective of this study was to investigate the role of mediastinal radiation therapy in patients who achieve a complete response (CR) to chemotherapy.The authors reviewed 47 patients with mediastinal T-cell LBL with or without bone marrow (BM) involvement who presented between 1980 and 1998. The median patient age was 25 years, and 33 patients (70%) were males. BM involvement was present in 16 patients (34%), 5 patients (11%) were in leukemic phase, lymph node involvement in was present 23 patients (49%), hepatosplenomegaly was present in 4 patients (9%), and pleural effusions were present in 22 patients (45%). The initial chemotherapy regimens were fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in 23 patients; cyclophosphamide, vincristine, doxorubicin, and dexamethasone in 9 patients; vincristine, doxorubicin, and dexamethasone in 4 patients; cyclophosphamide, doxorubicin, vincristine, and prednisone in 4 patients; and other in 7 patients. Forty-three patients achieved a CR to chemotherapy and were the subject of this analysis. Nineteen of those patients received adjuvant mediastinal radiation therapy at a dose ranging from 26 grays (Gy) to 39 Gy.There was no difference in patient characteristics between the 19 patients who were treated with mediastinal radiation therapy and the 24 patients who did not receive mediastinal radiation therapy. The median follow-up for all 43 patients was 43 months. The 5-year overall survival (OS) rate was 66%, and the freedom from progression (FFP) rate was 64%. None of 19 patients who received radiation therapy experienced a mediastinal recurrence compared with 8 of 24 patients who did not receive radiation therapy and experienced a mediastinal recurrence. Patients who were treated with mediastinal radiation therapy had a significantly better mediastinal FFP rate (P = 0.01), but the differences in overall FFP and OS rates were not significant (P = 0.14 and P = 0.25, respectively). The effectiveness of the hyper-CVAD regimen seemed to underscore the role of mediastinal radiation therapy; only 2 patients experienced a recurrence among 16 patients who received mediastinal radiation therapy, both outside the mediastinum. This compared with two patients who experienced a recurrence among six patients who did not receive mediastinal radiation therapy, both in the mediastinum.Local radiation therapy significantly decreased the risk of mediastinal recurrence in adult patients with mediastinal T-cell lymphoblastic lymphoma. The benefit of adjuvant radiation therapy was particularly evident in patients treated with more intensive chemotherapy regimens." @default.
• W2092120000 created "2016-06-24" @default.
• W2092120000 creator A5007688820 @default.
• W2092120000 creator A5008503600 @default.
• W2092120000 creator A5015140142 @default.
• W2092120000 creator A5034765756 @default.
• W2092120000 creator A5038307470 @default.
• W2092120000 creator A5040275365 @default.
• W2092120000 creator A5056014203 @default.
• W2092120000 creator A5066313849 @default.
• W2092120000 creator A5084379902 @default.
• W2092120000 creator A5085488112 @default.
• W2092120000 date "2002-05-14" @default.
• W2092120000 modified "2023-10-18" @default.
• W2092120000 title "The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma" @default.
• W2092120000 cites W125465197 @default.
• W2092120000 cites W1672417844 @default.
• W2092120000 cites W1786157004 @default.
• W2092120000 cites W1804278161 @default.
• W2092120000 cites W1824227359 @default.
• W2092120000 cites W1862517694 @default.
• W2092120000 cites W1864262809 @default.
• W2092120000 cites W1963865052 @default.
• W2092120000 cites W1972105236 @default.
• W2092120000 cites W1973395799 @default.
• W2092120000 cites W2036404799 @default.
• W2092120000 cites W2038879439 @default.
• W2092120000 cites W2052471794 @default.
• W2092120000 cites W2060372726 @default.
• W2092120000 cites W2088223293 @default.
• W2092120000 cites W2093958150 @default.
• W2092120000 cites W2110034478 @default.
• W2092120000 cites W2124303054 @default.
• W2092120000 cites W2198693965 @default.
• W2092120000 cites W2213539131 @default.
• W2092120000 cites W2310146029 @default.
• W2092120000 cites W2321358810 @default.
• W2092120000 cites W4293241248 @default.
• W2092120000 cites W9641470 @default.
• W2092120000 doi "https://doi.org/10.1002/cncr.10552" @default.
• W2092120000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12173345" @default.
• W2092120000 hasPublicationYear "2002" @default.
• W2092120000 type Work @default.
• W2092120000 sameAs 2092120000 @default.
• W2092120000 citedByCount "48" @default.
• W2092120000 countsByYear W20921200002012 @default.
• W2092120000 countsByYear W20921200002013 @default.
• W2092120000 countsByYear W20921200002014 @default.
• W2092120000 countsByYear W20921200002015 @default.
• W2092120000 countsByYear W20921200002016 @default.
• W2092120000 countsByYear W20921200002017 @default.
• W2092120000 countsByYear W20921200002018 @default.
• W2092120000 countsByYear W20921200002020 @default.
• W2092120000 countsByYear W20921200002021 @default.
• W2092120000 countsByYear W20921200002022 @default.
• W2092120000 countsByYear W20921200002023 @default.
• W2092120000 crossrefType "journal-article" @default.
• W2092120000 hasAuthorship W2092120000A5007688820 @default.
• W2092120000 hasAuthorship W2092120000A5008503600 @default.
• W2092120000 hasAuthorship W2092120000A5015140142 @default.
• W2092120000 hasAuthorship W2092120000A5034765756 @default.
• W2092120000 hasAuthorship W2092120000A5038307470 @default.
• W2092120000 hasAuthorship W2092120000A5040275365 @default.
• W2092120000 hasAuthorship W2092120000A5056014203 @default.
• W2092120000 hasAuthorship W2092120000A5066313849 @default.
• W2092120000 hasAuthorship W2092120000A5084379902 @default.
• W2092120000 hasAuthorship W2092120000A5085488112 @default.
• W2092120000 hasBestOaLocation W20921200001 @default.
• W2092120000 hasConcept C126322002 @default.
• W2092120000 hasConcept C126838900 @default.
• W2092120000 hasConcept C141071460 @default.
• W2092120000 hasConcept C143998085 @default.
• W2092120000 hasConcept C203014093 @default.
• W2092120000 hasConcept C2776090121 @default.
• W2092120000 hasConcept C2776694085 @default.
• W2092120000 hasConcept C2776755627 @default.
• W2092120000 hasConcept C2777478502 @default.
• W2092120000 hasConcept C2778720950 @default.
• W2092120000 hasConcept C2779338263 @default.
• W2092120000 hasConcept C2779429289 @default.
• W2092120000 hasConcept C2781303535 @default.
• W2092120000 hasConcept C509974204 @default.
• W2092120000 hasConcept C71924100 @default.
• W2092120000 hasConcept C8891405 @default.
• W2092120000 hasConcept C90924648 @default.
• W2092120000 hasConceptScore W2092120000C126322002 @default.
• W2092120000 hasConceptScore W2092120000C126838900 @default.
• W2092120000 hasConceptScore W2092120000C141071460 @default.
• W2092120000 hasConceptScore W2092120000C143998085 @default.
• W2092120000 hasConceptScore W2092120000C203014093 @default.
• W2092120000 hasConceptScore W2092120000C2776090121 @default.
• W2092120000 hasConceptScore W2092120000C2776694085 @default.
• W2092120000 hasConceptScore W2092120000C2776755627 @default.
• W2092120000 hasConceptScore W2092120000C2777478502 @default.
• W2092120000 hasConceptScore W2092120000C2778720950 @default.
• W2092120000 hasConceptScore W2092120000C2779338263 @default.
• W2092120000 hasConceptScore W2092120000C2779429289 @default.
• W2092120000 hasConceptScore W2092120000C2781303535 @default.

• next